347 related articles for article (PubMed ID: 22318201)
21. Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR-ABL-Negative Myeloproliferative Neoplasm.
Allegra A; Pioggia G; Tonacci A; Casciaro M; Musolino C; Gangemi S
Antioxidants (Basel); 2020 Oct; 9(11):. PubMed ID: 33114087
[TBL] [Abstract][Full Text] [Related]
22. Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms.
Skov V; Thomassen M; Kjaer L; Larsen MK; Knudsen TA; Ellervik C; Kruse TA; Hasselbalch HC
Eur J Haematol; 2023 Nov; 111(5):805-814. PubMed ID: 37640394
[TBL] [Abstract][Full Text] [Related]
23. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.
Skov V; Riley CH; Thomassen M; Kjær L; Stauffer Larsen T; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2017 Aug; 58(8):1914-1921. PubMed ID: 27911124
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
25. [Metamorphosis of chronic myeloproliferative diseases].
Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
[No Abstract] [Full Text] [Related]
26. Myeloproliferative neoplasms cause glomerulopathy.
Said SM; Leung N; Sethi S; Cornell LD; Fidler ME; Grande JP; Herrmann S; Tefferi A; D'Agati VD; Nasr SH
Kidney Int; 2011 Oct; 80(7):753-9. PubMed ID: 21654720
[TBL] [Abstract][Full Text] [Related]
27. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
28. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
29. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
Silver RT; Kiladjian JJ; Hasselbalch HC
Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
[TBL] [Abstract][Full Text] [Related]
30. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
31. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
[TBL] [Abstract][Full Text] [Related]
32. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
33. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
[TBL] [Abstract][Full Text] [Related]
34. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
Michiels JJ; Thiele J
Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
[TBL] [Abstract][Full Text] [Related]
35. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis.
Wang JC; Chen C; Novetsky AD; Lichter SM; Ahmed F; Friedberg NM
Am J Med; 1998 May; 104(5):451-5. PubMed ID: 9626028
[TBL] [Abstract][Full Text] [Related]
36. Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.
Bjørn ME; Andersen CL; Jensen MK; Hasselbalch HC
Eur J Haematol; 2014 Sep; 93(3):224-8. PubMed ID: 24689875
[TBL] [Abstract][Full Text] [Related]
37. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC; Pereira A; Gómez M; Boqué C; Ferrer-Marín F; Raya JM; García-Gutiérrez V; Kerguelen A; Xicoy B; Barba P; Martínez J; Luño E; Alvarez-Larrán A; Martínez-López J; Arbelo E; Besses C;
Haematologica; 2014 Apr; 99(4):e55-7. PubMed ID: 24488561
[No Abstract] [Full Text] [Related]
38. Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.
Battukh N; Ali E; Yassin M
Acta Biomed; 2022 Jan; 92(6):e2021478. PubMed ID: 35075062
[TBL] [Abstract][Full Text] [Related]
39. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
40. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
Hultdin M; Sundström G; Wahlin A; Lundström B; Samuelsson J; Birgegård G; Engström-Laurent A
Med Oncol; 2007; 24(1):63-70. PubMed ID: 17673813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
